Research and development based on modular drug discovery
First written in FY2019-Q2. 19 of 20 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「To realize this corporate philosophy, we will conduct research and development of anticancer drugs based on our proprietary "module drug discovery" approach.」
Reaffirms the policy of continuing anticancer drug research and development based on the proprietary "module drug discovery" approach. - FY2026-H1RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2025-H1RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2024-Q3RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2024-Q2RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2024-Q1RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2023-Q3RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2023-Q2RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2023-Q1RestatedAnnual report
「As concerns grow over cancer treatment for an aging patient population and the cost of increasingly expensive new drugs, we pursued research and development based on our "module drug discovery" approach and steadily advanced the clinical development of each pipeline, with the aim of providing treatments that patients can recommend to family members with cancer without financial concerns.」
Continues research and development based on the "module drug discovery" approach. - FY2022RestatedAnnual report
「To realize this corporate philosophy, we will conduct research and development of anticancer drugs based on our proprietary "module drug discovery" approach.」
Continues research and development of anticancer drugs based on the proprietary "module drug discovery" approach. - FY2022-Q3RestatedAnnual report
「We pursued research and development based on our “modular drug discovery” approach and steadily advanced clinical development.」
Continues research and development based on the "module drug discovery" approach. - FY2022-Q2RestatedAnnual report
「We pursued research and development based on our “modular drug discovery” approach and steadily advanced clinical development.」
Continues research and development based on the "module drug discovery" approach. - FY2022-Q1RestatedAnnual report
「We pursued research and development based on our “modular drug discovery” approach and steadily advanced clinical development.」
Continues research and development based on the "module drug discovery" approach. - FY2021RestatedAnnual report
「Modular drug discovery for anticancer drugs involves combining active substances from anticancer drugs that have already been developed into medicines. As a result, little basic exploratory research is required, and clinical efficacy and safety can be predicted. Clinical trials can therefore begin within 1–2 years of starting development, making the research and development process more efficient and shorter than for conventional anticancer drugs and reducing the risk of development failure, including failure in clinical trials.」
Details the mechanism of modular drug discovery: limited basic research, initiation of clinical trials within 1–2 years, shorter development timelines and lower risk. The underlying theme remains unchanged. - FY2020-Q3RestatedAnnual report
「We pursued research and development based on our "module drug discovery" approach and steadily advanced our development pipeline.」
Continues research and development based on the "module drug discovery" approach. - FY2020-Q2RestatedAnnual report
「We pursued research and development based on our “modular drug discovery” approach and steadily advanced clinical development.」
Continues research and development based on the "module drug discovery" approach. - FY2020-Q1RestatedAnnual report
「We pursued research and development based on our “modular drug discovery” approach and steadily advanced clinical development.」
Continues research and development based on the "module drug discovery" approach. - FY2019RestatedAnnual report
「To realize this corporate philosophy, we will conduct research and development of anticancer drugs based on our proprietary "module drug discovery" approach.」
Continues to position "module drug discovery" as the company's proprietary drug discovery method. - FY2019-Q3RestatedAnnual report
「We pursued research and development based on our “modular drug discovery” approach and steadily advanced clinical development.」
Continues to identify "module drug discovery" as the company's drug discovery approach. - FY2019-Q2First statedAnnual report
「We pursued research and development based on our “modular drug discovery” approach and steadily advanced clinical development.」
Explicitly identifies “modular drug discovery” as the company’s drug-discovery approach.